Liposomal Formulations in Clinical Use: An Updated Review.
Liposomal Formulations in Clinical Use: An Updated Review.
复制标题
DOI：
10.3390/pharmaceutics9020012
复制
发表时间：
2017-03-27
期刊：
影响因子：
5.4
通讯作者：
Khan W
中科院分区：
文献类型：
--
作者：
Bulbake U;Doppalapudi S;Kommineni N;Khan W
脂质体是第一个已成功转化为实时临床应用的纳米药物递送系统。这些封闭的双层磷脂囊泡自1965年首次开发以来，近年来已经见证了许多技术进步。通过脂质体递送治疗剂改变了它们的生物分布特征，这进一步增强了各种药物的治疗指数。正在进行广泛的研究，使用这些纳米药物输送系统在不同的领域，包括抗癌，抗真菌，抗炎药物和治疗基因的交付。脂质体作为药物递送系统在医疗保健领域中的显著贡献是许多临床产品已知的，例如，Doxil®、Ambisome®、DepoDur™等。这篇综述提供了脂质体技术的详细更新，例如，DepoFoam™技术、Stealth技术等，临床使用产品的配方方面和正在进行的脂质体临床试验。
Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil®, Ambisome®, DepoDur™, etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam™ Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes.